On Monday, October 27, 2025, Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single‑ascending dose/multiple‑ascending dose (SAD/MAD) study of its second M4 muscarinic receptor positive allosteric modulator, NMRA‑898. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and is the first clinical assessment of this structurally distinct compound within the company’s M4 franchise.
The M4 franchise currently includes two highly potent and selective M4 PAMs—NMRA‑861 and the newly launched NMRA‑898—both of which aim to provide an improved therapeutic profile for schizophrenia and other neuropsychiatric disorders compared to standard of care. Pre‑clinical studies of NMRA‑898 reported no convulsions in multiple species, including rabbits, supporting its safety profile as the program moves into human trials.
Neumora plans to use the data from the NMRA‑898 study to evaluate its overall M4 strategy, potentially advancing one or both programs. The company also announced that it will provide a comprehensive franchise update by mid‑2026, underscoring the importance of this milestone for guiding future development and investment decisions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.